INVESTOR ALERT: Investigation on Behalf of Investors of Sanofi Announced by Glancy Binkow & Goldberg LLP

Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Sanofi (the “Company”) (NYSE:SNY) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Sanofi between February 7, 2013 and December 3, 2014, concerning the Company’s operations and financial performance.

Please contact Casey Sadler at (310) 201-9150, or at shareholders@glancylaw.com to discuss this matter. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

Sanofi discovers, develops and distributes therapeutic solutions, including pharmaceuticals and vaccines used by veterinarians, consumer health care products, and generic medicines. The investigation is related to allegations that Sanofi misrepresented or failed to disclose that the Company was making improper payments to healthcare professionals in connection with the sale of pharmaceutical products, in violation of federal law, and that Sanofi’s internal controls over financial reporting were inadequate.

If you purchased Sanofi shares between February 7, 2013 and December 3, 2014, if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at (310) 201-9150, Toll Free at (888) 773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.